SARRP Used in In Vivo PARP Inhibitor Research

February 28, 2022

In the recent publication, Zebrafish as an in vivo screening tool to establish PARP inhibitor efficacy, researchers examined treatment modalities to aid the development of PARP inhibitors. These compounds target tumors deficient in the Homologous Recombination pathway, which are associated with increased risk for breast, ovarian, pancreatic and prostate cancer.

See more below and the full article here.

Contact Us

Find out more about how Xstrahl will work tirelessly for you

Explore Related Posts